By a News Reporter-Staff News Editor at Biotech Week Investigators discuss new findings in Drugs and Therapies - Biosimilars. According to news reporting originating in Portola Valley, California, by NewsRx journalists, research stated, "A systematic review was conducted to explore the immunogenicity of biologic agents across inflammatory diseases and its potential impact on efficacy/safety. Literature searches were conducted through November 2016 to identify controlled and observational studies of biologics/biosimilars administered for treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), psoriasis (Ps), Crohn's disease, and ulcerative colitis."
Financial support for this research came from Pfizer (see also Drugs and Therapies - Biosimilars).
The news reporters obtained a quote from the research from Stanford University, "Of > 21,000 screened publications, 443 were included. Anti-drug antibody (ADAb) rates varied widely among biologics across diseases (and are not directly comparable because of immunoassay heterogeneity); the highest overall rates were reported with infliximab (0-83%), adalimumab (0-54%), and infliximab biosimilar CT-P13 (21-52%), and the lowest with secukinumab (0-1%), ustekinumab (1-11%), etanercept (0-13%), and golimumab (0-19%). Most ADAbs were neutralizing, except those to abatacept and etanercept. ADAb+ versus ADAb- patients had lower rates of clinical response to adalimumab (RA, PsA, JIA, AS, Ps), golimumab (RA), infliximab (RA, PsA, AS, Ps), rituximab (RA), ustekinumab (Ps), and CT-P13 (RA, AS). Higher rates of infusion-related reactions were reported in infliximab- and CT-P13-treated ADAb+ patients. Background immunosuppressives/anti-proliferatives reduced biologic immunogenicity across diseases. Based on reviewed reports, biologic/biosimilar immunogenicity differs among agents, with the highest rates observed with infliximab and adalimumab."
According to the news reporters, the research concluded: "As ADAb formation in biologic-/biosimilar-treated patients may increase the risk of lost response, the immunogenicity of these agents is an important (albeit not the only) consideration in the treatment decision-making process."
For more information on this research see: Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. Biodrugs, 2017;31(4):299-316. Biodrugs can be contacted at: Adis Int Ltd, 5 The Warehouse Way, Northcote 0627, Auckland, New Zealand.
Our news correspondents report that additional information may be obtained by contacting V. Strand, Stanford University, Div Immunol Rheumatol, Sch Med, Portola Valley, CA 94028, United States. Additional authors for this research include A. Balsa, J. Al-Saleh, L. Barile-Fabris, T. Horiuchi, T. Takeuchi, S. Lula, C. Hawes, B. Kola and L. Marshall.
Keywords for this news article include: Portola Valley, California, United States, North and Central America, Musculoskeletal Diseases and Conditions, Ankylosing Spondylitis, Article Review, Tumor Necrosis Factor (TNF) Inhibitors, Autoimmune Diseases and Conditions, Genetically-Engineered Proteins, Joint Diseases and Conditions, Monoclonal Antibodies, Rheumatoid Arthritis, Genetic Engineering, Drugs and Therapies, Immunologic Agents, Pharmaceuticals, Bioengineering, Antirheumatics, Biotechnology, Immunotherapy, Biosimilars, Adalimumab, Infliximab, Biologics, Golimumab, Stanford University.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC